UK government rejects calls for independent inquiry into NICE’s work
This article was originally published in SRA
The UK government has rejected concerns raised by pharma and biotech companies that the cost-effective approach being followed by the country’s health technology assessment body, the National Institute for Health and Clinical Excellence, may be stifling innovation. It has declined calls for an independent inquiry to assess the long-term impact of NICE’s work on the industry1,2.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.